** U.S.-listed shares of Israel-based drug developer NeuroSense Therapeutics NRSN.O rise 6.3% to 80 cents

** NRSN says its experimental oral drug PrimeC for amyotrophic lateral sclerosis (ALS), showed a statistically significant reduction in TDP-43 versus placebo, meeting the main goal of a mid-stage study

** ALS is a fatal nerve disease that causes progressive muscle weakness and paralysis; TDP-43 is a disease-linked protein found in most ALS cases

** PrimeC is made from a fixed-dose combination of two FDA-approved drugs, ciprofloxacin and celecoxib - NRSN

** Co says findings build on earlier data showing slower disease progression, survival benefit and no new safety concerns

** Says it has FDA clearance to start a global late-stage ALS study, expects to enroll about 300 patients mostly in the U.S.

** Including session's move, NRSN up 16.4% YTD